AstraZeneca Results Presentation Deck
Oncology: 'What's next'
Solid pipeline moving forward
What's next
Phase I/II new medicines, selected
adavosertib
(WEE1¹ inhibitor)
uterine, ovarian cancer
oleclumab
(CD73² mAb)
solid tumours
AZD4573
(CDK93 inhibitor)
blood cancers
MEDI2228
(BCMA4 ADC5)
blood cancers
AZD5991
(MCL16 inhibitor)
blood cancers
ceralasertib
(ATR7 inhibitor)
solid tumours, blood cancers
AZD4635
(A2AR8 inhibitor)
solid tumours
MEDI5752
(PD-19/CTLA4¹0 mAb)
solid tumours
AZD2811
(Aurora B inhibitor)
solid tumours, blood cancers
AZD0466
(Bcl-2¹¹/XL)
solid tumours, blood cancers
What's now
datopotamab deruxtecan
lung cancer
monalizumab
head & neck cancer
savolitinib
NSCLC¹2
Now PIII
Tagrisso
NSCLC
Imfinzi
multiple cancers
Phase III new medicines
camizestrant (AZD9833
breast cancer
capivasertib
breast, prostate cancer
tremelimumab
multiple cancers
Phase III lifecycle management, major
Lynparza
multiple cancers
Enhertu
Now PIII
multiple cancers
Calquence
multiple cancers
1. Tyrosine kinase WEE1 2.5'-nucleotidase 3. Cyclin-dependent kinase 9 4. B-cell maturation antigen 5. Antibody drug conjugate 6. Induced myeloid leukaemia cell differentiation protein 7. Ataxia telangiectasia and rad3-related kinase 8. Adenosine A2A receptor
9. Programmed cell death protein 1 10. Cytotoxic T-lymphocyte-associated protein 4 11. B-cell lymphoma 2 12. Potentially pivotal Phase II.
33View entire presentation